CAN FITE BIOPHARMA LTD-ADR (CANF) Stock Price & Overview
NYSEARCA:CANF • US13471N3008
Current stock price
The current stock price of CANF is 2.92 USD. Today CANF is down by -2.67%. In the past month the price decreased by -9.88%. In the past year, price decreased by -87.08%.
CANF Key Statistics
- Market Cap
- 6.256M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -4.59
- Dividend Yield
- N/A
CANF Stock Performance
CANF Stock Chart
CANF Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to CANF. When comparing the yearly performance of all stocks, CANF is a bad performer in the overall market: 97.12% of all stocks are doing better.
CANF Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CANF. While CANF seems to be doing ok healthwise, there are quite some concerns on its profitability.
CANF Earnings
CANF Forecast & Estimates
For the next year, analysts expect an EPS growth of 100% and a revenue growth 290391% for CANF
CANF Groups
Sector & Classification
CANF Financial Highlights
Over the last trailing twelve months CANF reported a non-GAAP Earnings per Share(EPS) of -4.59. The EPS increased by 45.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -103.3% | ||
| ROE | -175.75% | ||
| Debt/Equity | 0 |
CANF Ownership
CANF Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.83 | 360.314B | ||
| AMGN | AMGEN INC | 15.1 | 188.978B | ||
| GILD | GILEAD SCIENCES INC | 15.08 | 168.645B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.42 | 111.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.94 | 79.228B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.19 | 41.489B | ||
| INSM | INSMED INC | N/A | 30.828B | ||
| NTRA | NATERA INC | N/A | 29.443B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.978B | ||
| BIIB | BIOGEN INC | 11.53 | 26.907B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.62 | 25.134B | ||
| MRNA | MODERNA INC | N/A | 21.65B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.477B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the NYSE Arca Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CANF
Company Profile
Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The firm co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
Company Info
IPO: 2005-09-22
CAN FITE BIOPHARMA LTD-ADR
10 Bareket Street, Kiryat Matalon, P.O. Box 7537
Petah Tikva 4951778 IL
CEO: Pnina Fishman
Employees: 5
Phone: 97239241114
CAN FITE BIOPHARMA LTD-ADR / CANF FAQ
Can you describe the business of CAN FITE BIOPHARMA LTD-ADR?
Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The firm co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
What is the current price of CANF stock?
The current stock price of CANF is 2.92 USD. The price decreased by -2.67% in the last trading session.
Does CANF stock pay dividends?
CANF does not pay a dividend.
What is the ChartMill technical and fundamental rating of CANF stock?
CANF has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is CAN FITE BIOPHARMA LTD-ADR worth?
CAN FITE BIOPHARMA LTD-ADR (CANF) has a market capitalization of 6.26M USD. This makes CANF a Nano Cap stock.
Can you provide the ownership details for CANF stock?
You can find the ownership structure of CAN FITE BIOPHARMA LTD-ADR (CANF) on the Ownership tab.